An ESMO-EORTC position paper on the EU clinical trials regulation and EMA's transparency policy: making European

C Dittrich1, A Negrouk2, P G Casali3

  • 1European Society for Medical Oncology (ESMO), Lugano, Switzerland; Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna)-LB Cluster Translational Oncology, Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria.

Abstract

No abstract available in PubMed .

Related Concept Videos